Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 12/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3126537 | 0.78 | HTT (0.50) | PRKCQATMTDP1L3MBTL1ALDH1A1 | |
| SCHEMBL15120574 | 0.70 | EGFR (0.53) | PRKCQL3MBTL1POLBMAPTEGFR | |
| SCHEMBL3024002 | 0.70 | JAK2 (0.39) | ALDH1A1HTT | |
| SCHEMBL3666467 | 0.70 | JAK2 (0.39) | ALDH1A1HTT | |
| SCHEMBL3670923 | 0.68 | NTRK1 (0.36) | PRKCQATMTDP1L3MBTL1ALDH1A1 | |
| SCHEMBL3008853 | 0.68 | NTRK1 (0.36) | PRKCQATMTDP1L3MBTL1ALDH1A1 | |
| SCHEMBL3671586 | 0.68 | JAK3 (0.42) | PRKCQ | |
| SCHEMBL3009495 | 0.68 | JAK3 (0.42) | PRKCQ | |
| SCHEMBL2568578 | 0.66 | TDP1 (0.50) | ATMTDP1L3MBTL1ALDH1A1POLB | |
| SCHEMBL30731666 | 0.66 | TDP1 (0.50) | ATMTDP1L3MBTL1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204246-A1 | 5-AMINOPYRAZOL-3-YL-3H-IMIDAZO (4,5-B) PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-08-12 | — | — | US | disclosed |
| EP-2155742-A1 | 5-AMINOPYRAZOL-3-YL-3H-IMIDAZO [4,5-B]PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008129255-A1 | 5-AMINOPYRAZOL-3-YL-3H-IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204246-A1 | 5-AMINOPYRAZOL-3-YL-3H-IMIDAZO (4,5-B) PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ABL1, MCL1, ETV6 | PRKCQ 783/4885ATM 729/4885TDP1 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.